The scope of reproductive care now widely encompasses preeclampsia screening. This is projected to drive the U.S. preeclampsia laboratory testing market. Undiagnosed and untreated preeclampsia has been a major cause for foetal and maternal mortality. This can be prevented through efficient preeclampsia diagnosis. Additionally, the number of COVID-19 positive pregnant women is on the rise which is increasing their chances of developing this fatal condition.

Check Complete Report Details of market @ https://www.fairfieldmarketresearch.com/report/us-preeclampsia-laboratory-testing-market

The U.S. preeclampsia laboratory testing market will rise at a heathy CAGR of 5.1% during the forecast period of 2021-2026, reaching the market volume of 4,629,000 by 2026. As countries undergo an escalated rate of health-related risks, preeclampsia is reported as the third leading cause of maternal mortality in the U.S alone. According to Fairfield Market Research, the U.S. preeclampsia laboratory testing market will be worth US$3,040.5 Mn by 2026.

Higher Caseload of Preeclampsia-Related Births Fuels U.S. Market

The U.S. preeclampsia laboratory testing market primarily benefits from high prevalence of severe preeclampsia coupled with several product launches to cater to this surging caseload. Cases of severe preeclampsia have been mushrooming in recent times, generating palpable alarm across the healthcare sector. The Centres for Disease Control and Prevention states that preeclampsia is seen in every 1 in 25 pregnancies in the U.S. Furthermore, it’s also the cause of 15% premature births in the country.

Blood Tests to Hold Significant Share in U.S. Preeclampsia Laboratory Testing Market

Blood tests hold a sizeable lead in the test type category of the preeclampsia laboratory testing market and this propensity is not projected to undergo major deviances in the times to follow. Patients opt for blood tests over other options because of their higher accuracy rates. The report states that the blood test segment is expected to register a CAGR of 7.6% between the forecast period of 2021 and 2026.

Proactive Healthcare Workforce and Robust Infrastructure Favours Growth of U.S. Preeclampsia Laboratory Testing Market

The healthcare industry in the U.S. has played a preeminent role in improving preeclampsia laboratory testing across the region. The presence of numerous patient advocacy groups as well as government initiatives to develop better diagnostics regimen in the U.S. are strong contributors to the regional market’s dominance. The US Preventive Services Task Force has been making dedicated efforts to ensure proper management of screening tests. This is a critical success factor for the growth of the regional market. The regional market is also expected to witness rife growth opportunities, attracting interest of healthcare and pharmaceutical companies active in preeclampsia laboratory testing segment.

Table of Content

1. Executive Summary
1.1. U.S. Preeclampsia Laboratory Testing Market Outlook, 2018 - 2026 (US$ Million) and Volume (,000)
1.2. U.S. Preeclampsia Laboratory Testing Market Snapshot
1.3. U.S. Preeclampsia Laboratory Testing Market Incremental Opportunity, 2018 - 2026 (US$ Million) and Volume (,000)
1.4. Key Industry Trends

2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.3. Market Landscape
2.4. Preeclampsia Diagnostics Overview
2.5. MicroRNAs: Promising Biomarker in Preeclampsia
2.6. Medical Management of Preeclampsia: An Overview
2.7. Women’s Attitudes, Beliefs and Values About Tests, And Management for Hypertensive Disorders Of Pregnancy

TOC Continued...!!!

Companies Dominating the Global Market for Preeclampsia Laboratory Testing Reported to be Headquartered in the U.S

Two of the three companies that take up a sixty percent of the global preeclampsia laboratory market have their headquarters in the U.S. These are ThermoFischer Scientific and PerkinElmer along with their Swiss competitor F. Hoffmann-La Roche.

Moreover, several companies involved in the concerned testing are offering effective diagnostics through collaborations with esteemed research organizations in the region. Along with this, SERA Prognostics, Siemens Healthineers AG, Progenity Inc., Metabolomic Diagnostics Ltd., DiabetOmics Inc., and Bayer AG are some of the big names operating in the U.S. preeclampsia laboratory market.

Request a Sample Copy of this Report @ https://www.fairfieldmarketresearch.com/report/us-preeclampsia-laboratory-testing-market/request-sample

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

Contact

Fairfield Market Research

London, UK

UK +44 (0)20 30025888

USA +1 (844) 3829746 (Toll-free)

Web: https://www.fairfieldmarketresearch.com/

Email: [email protected]

Follow Us: LinkedIn